Sei Investments Co. Purchases 116,530 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sei Investments Co. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 760,358 shares of the biopharmaceutical company's stock after buying an additional 116,530 shares during the quarter. Sei Investments Co. owned about 0.06% of Gilead Sciences worth $70,235,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Bank of America boosted their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Remove Ads

Gilead Sciences Trading Up 1.7 %

GILD stock traded up $1.89 during midday trading on Thursday, hitting $111.16. The company had a trading volume of 6,382,732 shares, compared to its average volume of 6,810,437. The stock has a market cap of $138.43 billion, a price-to-earnings ratio of 300.43, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50 day moving average price is $104.69 and its 200 day moving average price is $94.46.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 302,785 shares of company stock valued at $30,503,250 in the last 90 days. Insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.